Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,618 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
C5b-9 and MASP2 deposition in skin and bone marrow microvasculature characterize hematopoietic stem cell transplant-associated thrombotic microangiopathy.
Elhadad S, Chadburn A, Magro C, Van Besien K, Roberson EDO, Atkinson JP, Terry H, Greenberg J, Reid W, Chapin J, Copertino D, Geramfard S, Rodriguez LB, Orfali N, Gerghis U, Shore T, Mayer S, Ahamed J, Laurence J. Elhadad S, et al. Among authors: greenberg j. Bone Marrow Transplant. 2022 Sep;57(9):1445-1447. doi: 10.1038/s41409-022-01723-5. Epub 2022 Jun 4. Bone Marrow Transplant. 2022. PMID: 35661836 No abstract available.
High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma.
Gomez-Arteaga A, Mark TM, Guarneri D, Christos PJ, Gergis U, Greenberg JD, Hsu J, Mayer SA, Niesvizky R, Pearse RN, Phillips AA, Rossi A, Coleman M, van Besien K, Shore TB. Gomez-Arteaga A, et al. Among authors: greenberg jd. Bone Marrow Transplant. 2019 Dec;54(12):2027-2038. doi: 10.1038/s41409-019-0587-0. Epub 2019 Jun 12. Bone Marrow Transplant. 2019. PMID: 31190006 Clinical Trial.
A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma.
Mark TM, Reid W, Niesvizky R, Gergis U, Pearse R, Mayer S, Greenberg J, Coleman M, Van Besien K, Shore T. Mark TM, et al. Among authors: greenberg j. Biol Blood Marrow Transplant. 2013 May;19(5):831-7. doi: 10.1016/j.bbmt.2013.02.013. Epub 2013 Feb 20. Biol Blood Marrow Transplant. 2013. PMID: 23454184 Free PMC article. Clinical Trial.
A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma.
Mark TM, Guarneri D, Forsberg P, Rossi A, Pearse R, Perry A, Pekle K, Tegnestam L, Greenberg J, Shore T, Gergis U, Mayer S, Van Besien K, Ely S, Jayabalan D, Sherbenou D, Coleman M, Niesvizky R. Mark TM, et al. Among authors: greenberg j. Biol Blood Marrow Transplant. 2017 Jun;23(6):930-937. doi: 10.1016/j.bbmt.2017.03.007. Epub 2017 Mar 8. Biol Blood Marrow Transplant. 2017. PMID: 28285081 Free article. Clinical Trial.
Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia.
Hsu J, Artz A, Mayer SA, Guarner D, Bishop MR, Reich-Slotky R, Smith SM, Greenberg J, Kline J, Ferrante R, Phillips AA, Gergis U, Liu H, Stock W, Cushing M, Shore TB, van Besien K. Hsu J, et al. Among authors: greenberg j. Biol Blood Marrow Transplant. 2018 Feb;24(2):359-365. doi: 10.1016/j.bbmt.2017.10.040. Epub 2017 Nov 8. Biol Blood Marrow Transplant. 2018. PMID: 29128555 Free PMC article.
Sequential intensive chemotherapy followed by autologous or allogeneic transplantation for refractory lymphoma.
Orfali N, Jhanwar Y, Koo C, Pasciolla M, Baldo M, Cuvilly E, Furman R, Gergis U, Greenberg J, Guarneri D, Hsu JM, Leonard JP, Mark T, Mayer S, Maignan K, Martin P, Opong A, Pearse R, Phillips A, Rossi A, Ruan J, Rutherford SC, Ryan J, Suhu G, Van Besien K, Shore T. Orfali N, et al. Among authors: greenberg j. Leuk Lymphoma. 2021 Jul;62(7):1629-1638. doi: 10.1080/10428194.2021.1881516. Epub 2021 Feb 13. Leuk Lymphoma. 2021. PMID: 33586581
Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results.
Boulad F, Shore T, van Besien K, Minniti C, Barbu-Stevanovic M, Fedus SW, Perna F, Greenberg J, Guarneri D, Nandi V, Mauguen A, Yazdanbakhsh K, Sadelain M, Shi PA. Boulad F, et al. Among authors: greenberg j. Haematologica. 2018 May;103(5):770-777. doi: 10.3324/haematol.2017.187047. Epub 2018 Feb 1. Haematologica. 2018. PMID: 29419425 Free PMC article.
Safety and tolerability of velafermin (CG53135-05) in patients receiving high-dose chemotherapy and autologous peripheral blood stem cell transplant.
Schuster MW, Shore TB, Harpel JG, Greenberg J, Jalilizeinali B, Possley S, Gerwien RW, Hahne W, Halvorsen YD. Schuster MW, et al. Among authors: greenberg j. Support Care Cancer. 2008 May;16(5):477-83. doi: 10.1007/s00520-007-0325-9. Epub 2007 Aug 21. Support Care Cancer. 2008. PMID: 17710442 Clinical Trial.
Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results.
Boulad F, Shore T, van Besien K, Minniti C, Barbu-Stevanovic M, Fedus SW, Perna F, Greenberg J, Guarneri D, Nandi V, Mauguen A, Yazdanbakhsh K, Sadelain M, Shi PA. Boulad F, et al. Among authors: greenberg j. Haematologica. 2018 Sep;103(9):1577. doi: 10.3324/haematol.2018.199414. Haematologica. 2018. PMID: 30171018 Free PMC article. No abstract available.
Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with 131I-tositumomab.
Elstrom RL, Ruan J, Christos PJ, Martin P, Lebovic D, Osborne J, Goldsmith S, Greenberg J, Furman RR, Avram A, Putman R, Chapman E, Mazumdar M, Griffith K, Coleman M, Leonard JP, Kaminski MS. Elstrom RL, et al. Among authors: greenberg j. Leuk Lymphoma. 2015 Feb;56(2):342-6. doi: 10.3109/10428194.2014.914195. Epub 2014 Jun 17. Leuk Lymphoma. 2015. PMID: 24730538 Free PMC article. Clinical Trial.
2,618 results